A phase I study of STN1013600 ophthalmic solution in healthy adult male volunteer

A clinical trial of STN1013600 ophthalmic solution in healthy adult male volunteer for single and repeated dose - Phase I -

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210614

Enrollment

Registered

2022-02-18

Start date

2022-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia

Interventions

To assess the tolerability of STN1013600 ophthalmic solution, by single dose, dose escalation. Next, to assess the tolerability of STN1013600 ophthalmic solution, by repeat dose which meet safety crit

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Subjects who can comply with scheduled visits, the examination and observation as specified in the clinical study protocol

Exclusion criteria

Exclusion criteria: 1)Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective 2)Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator

Design outcomes

Primary

Measure	Time frame
Safety: Adverse events and adverse drug reactions	—

Contacts

Public ContactYukie Migita

Santen pharmaceutical co.,ltd

clinical@santen.co.jp+81-6-4802-9341

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026